Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Imugene ( (AU:IMU) ) has issued an update.
Imugene Limited has announced a proposed issue of new securities, comprising up to 25 new convertible notes and 7,812,500 new warrants, with a proposed issue date of 18 December 2025. The capital raising, to be conducted via a placement or similar structure, underscores the company’s ongoing use of equity-linked instruments to fund its operations and growth initiatives, with potential implications for its capital structure and existing shareholders as the additional securities come on line.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an ASX-listed biotechnology company focused on developing immuno-oncology therapies. It operates in the biopharmaceutical sector, concentrating on novel cancer treatments and leveraging capital market transactions to support its clinical and research programs.
Average Trading Volume: 2,053,203
Technical Sentiment Signal: Sell
Current Market Cap: A$99.33M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.